TSP-1-1223 A/G Polymorphism as a Potential Predictor of the Recurrence Risk of Bladder Cancer in a Chinese Population
Table 5
TSP-1-1223 A/G polymorphism and clinicopathological characteristics in patients with bladder cancer.
Clinicopathological characteristics
Genotypes (%)
Adjusted OR (95% CI)a
AA + AG
GG
Tumor stage
Nonmuscle invasive
407 (87.3)
59 (12.7)
1.00 (reference)
Muscle invasive
125 (87.4)
18 (12.6)
0.979
1.01 (0.57–1.78)
Tumor grade
Grade 1
264 (88.6)
34 (11.4)
1.00 (reference)
Grade 2
168 (86.6)
26 (13.4)
0.440
1.26 (0.71–2.23)
Grade 3
100 (85.5)
17 (14.5)
0.294
1.43 (0.73–2.79)
Number
Single
384 (88.1)
52 (11.9)
1.00 (reference)
Multiple
148 (85.5)
25 (14.5)
0.433
1.23 (0.73–2.07)
Size
<3 cm
345 (88.2)
46 (11.8)
1.00 (reference)
≥3 cm
187 (85.8)
31 (14.2)
0.367
1.24 (0.74–2.08)
CI: confidence interval; OR: odds ratio. Adjusted for age, gender, smoking, drinking status, and family history of cancer in logistic regression model.